Some people may have an allergic reaction to Trelegy Ellipta. This wasn’t reported in studies of Trelegy Ellipta but has happened since the drug was approved. Trelegy Ellipta is used long term to help keep your lung function from becoming worse. You’ll use it every day to reduce COPD symptoms.

The instructions for use of the inhaler provided below can be used for either the 30-dose inhaler (30 day supply) or the 7-dose inhaler (7 day supply). Your leaflet has a pictogram in this location showing the inhaler held in a pair of hands, with the inhaler cover slid to the fully open position. If symptoms arise in the period between doses, an inhaled, short-acting beta 2-agonist should be used for immediate relief. In the 24-week placebo-controlled study in patients with symptomatic COPD, umeclidinium bromide reduced the risk of a moderate/severe COPD exacerbation by 40% compared with placebo (analysis of time to first exacerbation; Hazard Ratio 0.6; 95% CI: 0.4, 1.0, p=0.035 *). The probability of having an exacerbation in patients receiving umeclidinium bromide at week 24 was 8.9% compared with 13.7% for placebo. These studies were not specifically designed to evaluate the effect of treatments on COPD exacerbations and patients were withdrawn from the study if an exacerbation occurred.

Therapeutic indication

Data from large asthma and COPD clinical trials were used to determine the frequency of adverse reactions associated with fluticasone furoate/vilanterol. In the asthma clinical development program a total of 7,034 patients were included in an integrated assessment of adverse reactions. In the COPD clinical development programme a total of 6,237 subjects were included in an integrated assessment of adverse reactions. It is not possible to accidentally take extra medicinal product or a double dose in one inhalation. Do not use ANORO to treat sudden symptoms of COPD. Always have a rescue inhaler with you to treat sudden symptoms. In a 24 week study (HZA113091) in adult and adolescent patients with uncontrolled persistent asthma both fluticasone furoate/vilanterol 92/22 micrograms given once daily in the evening and salmeterol/FP 50/250 micrograms given twice daily demonstrated improvements from baseline in lung function. Adjusted mean treatment increases from baseline in weighted mean 0-24 hours FEV 1 of 341 mL (fluticasone furoate/vilanterol) and 377 mL (salmeterol/FP) demonstrated an overall improvement in lung function over 24 hours for both treatments. The adjusted mean treatment difference of -37 mL between the groups was not statistically significant (p=0.162). For trough FEV 1 subjects in the fluticasone furoate/vilanterol group achieved a LS mean change from baseline of 281 mL and subjects in the salmeterol/FP group a change of 300 mL; (the difference in adjusted mean of -19 mL (95%CI:-0.073, 0.034) was not statistically significant (p=0.485). serious problems in people with asthma. People with asthma who take LABA medicines, such as vilanterol (one of the medicines in ANORO ELLIPTA), without also using a medicine called an inhaled corticosteroid, have an increased risk of serious problems from asthma, including death.

Before using ANORO ELLIPTA, tell your healthcare provider about all of your medical conditions, including if you:

More about Anoro Ellipta (umeclidinium / vilanterol)

Yes, Trelegy Ellipta is used to help manage asthma symptoms in adults. It’s also used to manage chronic obstructive pulmonary disease (COPD) symptoms. This use is described above in “ Is Trelegy Ellipta used for COPD?”